Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
All news
Pharmaceutical
Positive results from the Phase III program comprising the REVISIT and ASSEMBLE studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) have been released by US pharma giant Pfizer. 1 June 2023
Biotechnology
Positive clinical progress with donidalorsen, a late-stage investigational prophylactic therapy for hereditary angioedema (HAE), were announced this morning by US RNA-targeted drug developer Ionis Pharmaceuticals. 1 June 2023
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs). 1 June 2023
Biotechnology
As anticipated, Pfizer as secured US Food and Drug Administration approval for its bivalent RSV vaccine, targeting disease caused by RSV in people over the age of 60. 1 June 2023
Biotechnology
Dutch biotech firm Pharming said today that it has entered into a definitive agreement with Swiss pharma giant Novartis to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis. 1 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Pharmaceutical
Following a mixed advisory panel vote in late April, the US Food and Drug Administration FDA) said yesterday that it has approved UK pharma major AstraZeneca’s Lynparza (olaparib). 1 June 2023
Biotechnology
Industry analyst GlobalData has forecast rapid uptake of AbbVie’s Rinvoq (upadacitinib) following US Food and Drug Administration approval. 1 June 2023
Pharmaceutical
Swedish immunology company InDex Pharmaceuticals InDex Pharmaceuticals has signed a license agreement with the Japanese subsidiary of Viatris to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. 1 June 2023
Biotechnology
Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion of the Opioid Settlement Funds and use it for psychedelic research, specifically ibogaine for opioid addiction. 31 May 2023
Pharmaceutical
This year’s meeting of the American Society of Clinical Oncology (ASCO) kicks off on Friday, with the highly anticipated plenary session taking place on Sunday. 31 May 2023
Pharmaceutical
Shares of US biotech Amylyx Pharmaceuticals fell more than 3% by close of trading Tuesday and a further 2.2% to $23.51 in pre-market activity today, after it said that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment 31 May 2023
Pharmaceutical
In the runup to this year’s meeting of the American Society of Clinical Oncology (ASCO), drugmakers around the world are lifting the curtain on the data they plan to present at the event. 31 May 2023
Biotechnology
French pharma major Sanofi has presented new data at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrating that frexalimab, the firm’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase II trial of patients with relapsing multiple sclerosis (RMS). 31 May 2023
Pharmaceutical
Chinese artificial intelligence company XtalPi has agreed terms for a $250 million collaboration with Eli Lilly. 31 May 2023
Biotechnology
Belgium’s largest drugmaker UCB will present new long-term 52-week data from three Phase III studies of bimekizumab at the 2023 meeting of the European Congress of Rheumatology (EULAR). 31 May 2023
Biotechnology
US pharma giant Pfizer’s proposed $43 billion ($229 per share) acquisition of Seagen has won approval from the latter’s shareholders. 31 May 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk recently announced that the starter doses of its weight-management drug Wegovy (semaglutide) would be limited in the USA until September, in an effort to avoid supply shortages. 31 May 2023
Pharmaceutical
Given the emerging evidence on coronavirus SARS-CoV-2 variants and lessons learned from previous vaccine updates, international regulators have published a report highlighting the outcomes of their discussions on COVID-19 vaccines and the need for and strategy to update their composition. 31 May 2023
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals has decided to invest over 50 billion yen ($356 million) in total for two new manufacturing facilities at the Utsunomiya plant. 31 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze